TEL AVIV, Israel, Nov. 07, 2017 (GLOBE NEWSWIRE) — VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio webcast on Tuesday, November 14, 2017 at 8:30am Eastern Time to report third quarter ended September 30, 2017 financial results.
| Tuesday, November 14 @ 8:30am Eastern Time | |||||||
| Domestic: | 877-280-1254 | ||||||
| International: | 646-254-3366 | ||||||
| Conference ID: | 1013162 | ||||||
| Webcast: | https://edge.media-server.com/m6/p/avv5bjwq | ||||||
Replays, Available through November 28th:
Domestic: 888-203-1112
International: 719-457-0820
Replay Passcode: 1013162
About VBL
Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company’s lead oncology product candidate, ofranergene obadenovec (VB-111), is a first-in-class, targeted anti-cancer gene-therapy agent that is positioned to treat a wide range of solid tumors. It is conveniently administered as an IV infusion once every two months. It has been observed to be well-tolerated in >300 cancer patients and we have observed its efficacy signals in an “all comers” Phase 1 trial as well as in three tumor-specific Phase 2 studies. Ofranergene obadenovec is currently being studied in a Phase 3 pivotal trial for recurrent Glioblastoma, conducted under an FDA Special Protocol Assessment (SPA).
INVESTOR CONTACT:
Michael Rice
LifeSci Advisors, LLC
(646) 597-6979
